Glioblastoma is the most common kind of malignant brain tumor in adults. So far, no treatment has been able to make this ...

Autolus Therapeutics has secured US Food and Drug Administration (FDA) approval for Aucatzyl (obecaktagene autoleucel), its ...

A recent meta-analysis investigating cardiovascular complications in adults undergoing chimeric antigen receptor (CAR) T-cell ...

These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...

Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...

Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells—a type of cancer immunotherapy—that can be switched on to varying degrees of intensity and ...

Discover how next-generation "switchable" CAR-T cells could improve both the safety and efficacy of CAR-T therapies.

In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a recent study has identified a pivotal role for CD39 expression in ...

PHILADELPHIA, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Interius BioTherapeutics, a clinical-stage company engineering targeted, programmable vectors for the precision delivery of genetic medicines, today ...

These therapies, including chimeric antigen receptor (CAR) T-cell therapy, have performed well in cancers such as leukemias and lymphomas, but results have been less promising in solid tumors.

Chimeric antigen receptor (CAR)-expressing T cell treatments have led to efficient and persisting antitumor responses for several cancer types, and thus offer hope for improved ovarian cancer ...